WO2001007028A3 - Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate - Google Patents

Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate Download PDF

Info

Publication number
WO2001007028A3
WO2001007028A3 PCT/US2000/019849 US0019849W WO0107028A3 WO 2001007028 A3 WO2001007028 A3 WO 2001007028A3 US 0019849 W US0019849 W US 0019849W WO 0107028 A3 WO0107028 A3 WO 0107028A3
Authority
WO
WIPO (PCT)
Prior art keywords
retinoid receptor
prostate carcinoma
treatment
receptor antagonists
tumor
Prior art date
Application number
PCT/US2000/019849
Other languages
English (en)
Other versions
WO2001007028A2 (fr
Inventor
Roshantha A Chandraratna
Geoffrey Brown
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Priority to AU62280/00A priority Critical patent/AU6228000A/en
Publication of WO2001007028A2 publication Critical patent/WO2001007028A2/fr
Publication of WO2001007028A3 publication Critical patent/WO2001007028A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement du cancer de la prostate consistant à administrer une dose thérapeutiquement efficace d'un antagoniste de récepteurs de rétinoïdes. Par ailleurs, la présente invention concerne des méthodes destinées à inhiber le développement d'une cellule cancéreuse ou tumeur de la prostate, cette méthode consistant à faire réagir ladite cellule ou tumeur au contact d'une dose efficace d'un antagoniste de récepteurs de rétinoïdes.
PCT/US2000/019849 1999-07-23 2000-07-21 Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate WO2001007028A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62280/00A AU6228000A (en) 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14528799P 1999-07-23 1999-07-23
US60/145,287 1999-07-23

Publications (2)

Publication Number Publication Date
WO2001007028A2 WO2001007028A2 (fr) 2001-02-01
WO2001007028A3 true WO2001007028A3 (fr) 2001-08-30

Family

ID=22512422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019849 WO2001007028A2 (fr) 1999-07-23 2000-07-21 Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate

Country Status (2)

Country Link
AU (1) AU6228000A (fr)
WO (1) WO2001007028A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416933A (pt) 2003-11-25 2007-01-16 Novo Nordisk As composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente
PT1937244T (pt) 2005-09-30 2018-11-07 Io Therapeutics Llc Tratamento do cancro com agonistas específicos de rxr
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
US10092535B2 (en) 2015-10-31 2018-10-09 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
WO2017091762A1 (fr) 2015-11-25 2017-06-01 Io Therapeutics, Inc. Utilisation d'agonistes sélectifs de rar alpha, résistants à cyp26, dans le traitement du cancer
KR102549273B1 (ko) 2016-03-10 2023-06-28 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
AU2016396659B2 (en) 2016-03-10 2019-02-14 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
CA3026563C (fr) 2016-06-10 2023-11-28 Io Therapeutics, Inc. Composes retinoides et rexinoides selectifs du recepteur et modulateurs immunitaires pour l'immunotherapie du cancer
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
JP2020526551A (ja) 2017-07-13 2020-08-31 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せた免疫調節性レチノイド及びレキシノイド化合物
CN111148514A (zh) 2017-08-31 2020-05-12 Io治疗公司 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2023108012A1 (fr) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Utilisation d'un agoniste de rxr et de taxanes dans le traitement de cancers her2+

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024348A1 (fr) * 1995-12-29 1997-07-10 Vision Pharmaceuticals L.P. Acides carboxyliques et esters de ((3''-thioxacyclohex-1''-enyl))-but-3'-en-1'-ynyl)aryle et heteroaryle presentant une activite biologique de type retinoide
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999033821A1 (fr) * 1997-12-24 1999-07-08 Allergan Sales, Inc. Derives de benzopyrane et benzothyopyrane presentant une activite retinoïde de type antagoniste

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024348A1 (fr) * 1995-12-29 1997-07-10 Vision Pharmaceuticals L.P. Acides carboxyliques et esters de ((3''-thioxacyclohex-1''-enyl))-but-3'-en-1'-ynyl)aryle et heteroaryle presentant une activite biologique de type retinoide
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
WO1999033821A1 (fr) * 1997-12-24 1999-07-08 Allergan Sales, Inc. Derives de benzopyrane et benzothyopyrane presentant une activite retinoïde de type antagoniste

Also Published As

Publication number Publication date
AU6228000A (en) 2001-02-13
WO2001007028A2 (fr) 2001-02-01

Similar Documents

Publication Publication Date Title
WO2001007028A3 (fr) Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
WO2001030381A3 (fr) Utilisation d'inhibiteurs csf-1
ZA200109906B (en) Method for treating chronic pain using MEK inhibitors.
WO2001015678A3 (fr) Utilisation topique d'agonistes des kappa opioides afin de traiter les douleurs oculaires
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
ZA200109903B (en) Method for treating chronic pain using MEK inhibitors.
MXPA00011248A (es) Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento.
WO2004068931A3 (fr) Anticorps anti-amphireguline (ar) et leur utilisation dans le traitement du cancer et du psoriasis
IL147017A0 (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
EP1539234A4 (fr) Methodes de prevention ou de traitement de malignites cellulaires par administration d'antagonistes de cd2
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU2003273176A8 (en) Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
WO2003045434A3 (fr) Methode et composition permettant de potentialiser un analgesique opioide
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
WO2004084943A8 (fr) Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
EP1175616A4 (fr) Procedes pour le diagnostic et le traitement de tumeurs metastatiques de la prostate
WO2005011590A3 (fr) Compositions et procedes pour le retablissement de la sensibilite au traitement par antagonistes vis-a-vis de her2
WO2002092016A3 (fr) Usages therapeutiques d'antagonistes de rank
WO2002098362A3 (fr) Utilisation d'antagonistes rank dans le traitement du cancer
WO2001080813A3 (fr) Methodes de prevention et de traitement de l'alopecie provoquee par la chimiotherapie ou la radiotherapie
WO2001074296A3 (fr) Traitement de tumeurs non solides chez des mammiferes au moyen d'antagonistes de recepteur de facteur de croissance endothelial vasculaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP